A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.

Exclusion Criteria

• •Family history of seizure, epilepsy, brain or mental disease
• •Participant that has a medical history of any of the following: allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV, such as mannitol.
• •Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months
• •Any acute fever disease or infections in last 7 days
• •Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease
• •Hereditary angioneurotic edema or acquired angioneurotic edema
• •Urticaria in last one year
• •Asplenia or functional asplenia
• •Platelet disorder or other bleeding disorder may cause injection contraindication
• •Faint at the sight of blood or needles.
• •Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months
• •Prior administration of blood products in last 4 months
• •Prior administration of other research medicines in last 1 month
• •Prior administration of attenuated vaccine in last 1 month
• •Prior administration of inactivated vaccine in last 14 days
• •Current anti-tuberculosis prophylaxis or therapy
• •Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives